Suppr超能文献

[多发性骨髓瘤国际分期系统分析及其与122例中国患者的DS和IFM分期系统的比较]

[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].

作者信息

Deng Shu-Hui, Xu Yan, Mai Yu-Jie, Wang Ya-Fei, Zhao Yao-Zhong, Zou De-Hui, Qiu Lu-Gui

机构信息

Institute of Hematology, Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):217-21.

Abstract

OBJECTIVE

To verify applicability of the International Staging System (ISS) for multiple myeloma (MM) to 112 Chinese MM patients and compare ISS with Durie-Salmon (DS) and Intergroup Francophone du Myeloma (IFM) staging system in predicting prognosis.

METHODS

112 previously untreated MM patients in Blood Diseases Hospital of CAMS were analyzed according to ISS retrospectively.

RESULTS

  1. Serum beta2-microglobulin (beta2-MG) > or = 3.5 mg/L was an independent adverse prognostic factor for overall survival (OS), and serum albumin <35 g/L predicted for time to progression (TTP), 2) In the 58 cases having cytogenetic data, chromosome 13 aberration (Delta 13) was the only independent adverse prognostic factor for OS; 3) Factors significantly related to serum beta2-MG were serum creatinine, 24h urinary protein,body mass index (BMI) and performance status (PS); and those related to serum albumin were hemoglobin level, percentage of bone marrow plasma cells, lactate dehydrogenase(LDN), fever, PS, class of M-protein, serum phosphorus and BMI; 4) All traditional prognostic factors had no statistical difference between ISS stage II and III excepting for serum beta2-MG and creatinine, and 5/6 Delta 13 patients were classified to ISS stage II; 5) The median OS of ISS stage I, II, III were 69, 23 and 26 months (m) respectively, being no statistical difference between stage II and III; for DS system, 89.5% of patients were classified in stage III, being no statistical difference for OS between the stage I/II and III; while for IFM system, the median OS of low-, intermediate- and high-risk group were 69, 40 and 8 months respectively, being statistically different between high-risk and intermediate/ low-risk groups.

CONCLUSIONS

From the result of our limited analysis, the staging of ISS II and III seems unsuitable for Chinese MM patients. The IFM staging system ,which incorporates delta 13, is more effective than ISS, and DS staging system in predicting prognosis.

摘要

目的

验证国际骨髓瘤分期系统(ISS)对112例中国多发性骨髓瘤(MM)患者的适用性,并比较ISS与Durie-Salmon(DS)分期系统及法国骨髓瘤协作组(IFM)分期系统在预测预后方面的差异。

方法

对中国医学科学院血液病医院112例初治MM患者进行回顾性ISS分期分析。

结果

1)血清β2微球蛋白(β2-MG)≥3.5mg/L是总生存期(OS)的独立不良预后因素,血清白蛋白<35g/L可预测疾病进展时间(TTP);2)在58例有细胞遗传学数据的患者中,13号染色体缺失(Δ13)是OS的唯一独立不良预后因素;3)与血清β2-MG显著相关的因素有血清肌酐、24小时尿蛋白、体重指数(BMI)和体能状态(PS);与血清白蛋白相关的因素有血红蛋白水平、骨髓浆细胞比例、乳酸脱氢酶(LDH)、发热、PS、M蛋白类型、血清磷和BMI;4)除血清β2-MG和肌酐外,ISSⅡ期和Ⅲ期之间所有传统预后因素均无统计学差异,6例Δ13患者中有5例被归为ISSⅡ期;5)ISSⅠ期、Ⅱ期、Ⅲ期的中位OS分别为69、23和26个月,Ⅱ期和Ⅲ期之间无统计学差异;对于DS分期系统,89.5%的患者被归为Ⅲ期,Ⅰ/Ⅱ期和Ⅲ期之间OS无统计学差异;而对于IFM分期系统,低危、中危和高危组的中位OS分别为69、40和8个月,高危组与中/低危组之间有统计学差异。

结论

基于我们有限的分析结果,ISSⅡ期和Ⅲ期分期似乎不适用于中国MM患者。纳入Δ13的IFM分期系统在预测预后方面比ISS和DS分期系统更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验